Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Income Statement and Estimates

More financial data

Delayed Deutsche Boerse AG Other stock markets 07:20:49 09/06/26 pm AEST			5-day change	1st Jan Change
0.4400 ^EUR	+1.85%		-.--%	-43.88%

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.29M 2.64M 2.46M 4.67M 313M 4.75M 31.8M 12.32M 154M 12.36M 12.09M 530M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.53M 3.63M 3.39M 6.42M 431M 6.53M 43.75M 16.95M 211M 17M 16.63M 729M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	98.11%	Yield 2023 *	-	Yield 2024	-

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
08/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
15/12/22	Twitter to shut down newsletter product Revue next year	RE
06/12/22	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/10/22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

04/03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
26/02	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
10/12	Klarsen : ALKLA-Attribution gratuite de BSA	PU
09/12	Klarsen : ALKLA-ACTIVITE 3T2025	PU
28/11	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Stock Deutsche Boerse AG

Stocks

4YA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Other IT Services & Consulting

Financials

Company Profile

Income Statement and Estimates

01/07	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
01/07	La Bourse s'habitue à tout
01/07	Klarsen : ALKLA – Point d’information sur la publication des comptes annuels 2025 et la suspension de cotation – 30 Juin 2026
10/06	Klarsen : ALKLA – Report des résultats trimestriels et date de publication des comptes annuels – 9 Juin 2026
01/06	Klarsen : Information réglementée – 2026

1 day	+1.85%
1 month	-29.49%
3 months	-42.11%
6 months	-43.88%
Current year	-43.88%

1 month	0.43	0.46
Current year	0.2	1.07
1 year	0.2	1.07
3 years	0.2	3.83
5 years	0.2	3.83
10 years	0.2	4.14

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	+1.85%	-.--%	-	-	1.43M
IBM	+0.42%	+11.11%	-0.24%	+114.68%	269B
SNOWFLAKE INC.	-1.62%	+13.26%	+18.33%	+45.30%	90.53B
TATA CONSULTANCY SERVICES LTD.	+4.31%	-1.94%	-39.70%	-37.37%	75.45B
ACCENTURE PLC	+5.07%	+8.99%	-54.63%	-55.90%	80.24B
RELX PLC	-0.30%	-0.68%	-38.96%	-9.57%	55.22B
INFOSYS LIMITED	+5.64%	-1.49%	-35.22%	-22.06%	41.94B
FUJITSU LIMITED	+3.31%	+3.47%	-4.02%	+79.83%	34.58B
NEC CORPORATION	+5.50%	+9.43%	+0.62%	+201.51%	32.51B
HCL TECHNOLOGIES LIMITED	+4.24%	-3.21%	-37.26%	-9.25%	29.43B
Average	+2.84%	+0.72%	-21.23%	+34.13%	78.77B
Weighted average by Cap.	+1.88%	+3.28%	-14.99%	+49.70%

	2023	2024
Net sales	5.03M 5.75M 4.62M 4.3M 8.16M 548M 8.3M 55.57M 21.54M 269M 21.6M 21.13M 925M	6.31M 7.22M 5.8M 5.4M 10.25M 688M 10.42M 69.78M 27.04M 337M 27.12M 26.53M 1.16B
Net income	2.75M 3.15M 2.53M 2.36M 4.47M 300M 4.54M 30.41M 11.79M 147M 11.82M 11.56M 507M	-47.76K -54.66K -43.86K -40.9K -77.54K -5.2M -78.85K -528K -205K -2.55M -205K -201K -8.8M
Net Debt	-634K -726K -583K -543K -1.03M -69.12M -1.05M -7.01M -2.72M -33.9M -2.73M -2.67M -117M	1.08M 1.24M 992K 926K 1.75M 118M 1.78M 11.95M 4.63M 57.75M 4.64M 4.54M 199M